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Salvage of thrombosed dialysis access grafts with venous anas-
tomosis stents.
Background. Thrombosis of arteriovenous (AV) grafts
caused by stenosis at the venous anastomosis is a well-described
problem. Surgical thrombectomy and conventional angioplasty
with mechanical thrombectomy have provided good success
rates in achieving immediate graft patency but with gener-
ally dismal graft survival rates in the range of 11% to 36% at
6 months’ follow-up. The role of intravascular stents in patients
who have failed angioplasty or surgical revision at the venous
anastomosis has not been fully elucidated, particularly in older
grafts that have previously undergone multiple procedures.
Methods. In this series, 34 patients had self-expanding niti-
nol stents placed at the venous anastomosis following graft
thrombectomy and angioplasty procedures. Patients were se-
lected for stent placement if conventional angioplasty alone was
unsuccessful due to immediate elastic recoil or residual stenosis.
All patients were followed after stent placement and evaluated
for duration of graft patency and need for repeated endovascu-
lar procedures.
Results. The average graft age at the time of stent placement
was 17.9 months. Eight-eight percent of grafts were function-
ing at 6 months’ follow-up, and 63% of the entire group had
survived without the need for additional procedures. Among
those with need for repeat interventions, 81% had new lesions
outside of the stent, and 57% had new lesions within the stent.
In 38% of cases, new stenoses were located both outside and
within the stent. Among grafts no longer being used, only 19%
of the time was it due to disease recurring within the stent.
Conclusion. Polytetrafluoroethylene (PTFE) graft longevity
is improved when venous anastomosis stenoses are treated with
stents in selected cases of older grafts that would have normally
undergone abandonment or surgical revision
Dialysis access failure caused by acute thrombosis is a
common problem. In most scenarios of clotted arteriove-
nous (AV) grafts, a stenosis at the venous outlet of the
graft will have precipitated the event by leading to dimin-
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ished blood flow [1]. Attempts to reestablish circulation
in the AV graft fail unless this stenosis, usually caused by
hyperplasia of the vessel intima, is corrected. The litera-
ture abounds with a variety of approaches to handle an
acutely thrombosed graft. These range from open surgi-
cal thrombectomy alone to surgical revision of the anas-
tomosis between the graft and the native vein with patch
angioplasty or jump grafts to more proximal veins. Percu-
taneous procedures for thrombectomy with angioplasty
of severe stenoses have also gained much attention. Un-
fortunately, despite the many modalities used to treat AV
grafts, the long-term graft survival rates after thrombo-
sis remain dismally low, on the order of 11% to 36% at
6 months’ follow-up, regardless of whether endovascular
or surgical techniques were utilized [2–4]. Overall lifes-
pan of grafts from creation to the final thrombosis event is
also short, with estimates of unassisted patency of grafts at
2 years of only 24.6%, and graft survival (with additional
procedures performed) at 59.8% at 2 years of follow-up
[5]. Graft failure often occurs within 2 years of placement,
requiring new vascular access to be obtained [6, 7].
Because the sites for definitive vascular access are lim-
ited, attempts to improve access patency and survival are
essential. Salvage of grafts, rather than early abandon-
ment and creation of new accesses, is important. In this
regard, the exact role of different technologies, such as
intravascular stents, has not been clearly defined. This ob-
servational study evaluates graft patency and survival in
patients for whom intravascular stents have been placed
to treat lesions at the anastomosis of the AV graft to the
native vein following graft thrombosis.
METHODS
All patients presenting with clotted AV grafts during
an 18-month period were evaluated angiographically for
the presence or absence of venous anastomosis lesions. In
all patients in whom a significant lesion was found at the
anastomosis (greater than 50%), conventional balloon
angioplasty was performed. Mechanical thrombectomy
followed angioplasty of the venous anastomosis. In those
patients who had previously had angioplasty of the same
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lesion within 3 months who had lumens which collapsed
immediately after angioplasty (elastic recoil), or had sig-
nificant residual stenosis despite the use of angioplasty,
intravascular stent placement at the venous anastomo-
sis was performed prior to or immediately following me-
chanical thrombectomy of the graft and reestablishment
of flow within the graft. Cutting balloon angioplasty was
necessary in a small portion of cases to establish initial
patency at the anastomosis.
Specifically, access to the clotted AV graft was obtained
by placement of 7 French Brite-TipTM sheaths (Cordis
International, Miami, FL, USA) at the arterial aspect
of the graft in a direction toward the venous outflow.
The sheaths were placed via modified Seldinger tech-
nique. The venous anastomosis and the clotted graft it-
self were traversed with a guide wire, usually a floppy
0.035-in BentsonTM (Cook, Inc., Bloomington, IN, USA),
a hydrophilic GlidewireTM (Boston Scientific Corpora-
tion, Boston, MA, USA), or comparable stiffer guide
wire, depending on the specific needs of the individual
case. Angiography of the venous anastomosis was per-
formed through a guide catheter that had been inserted
over the wire and beyond the anastomosis, and pulled
back through the anastomosis as iodinated contrast was
released.
Angioplasty was usually performed with a PowerflexTM
balloon (Cordis International). These balloons had diam-
eters of 7 to 10 mm and lengths of 40 mm to 80 mm de-
pending upon the lesion size. Balloons were inflated to
maximal capacity, usually up to 15 atmospheres of pres-
sure. High-pressure balloons, namely the ConquestTM
balloon (Bard, Inc., Murray Hill, NJ, USA), were em-
ployed in a few cases in which the PowerflexTM balloon
achieved suboptimal results. These balloons had maxi-
mal burst pressures of 25 to 30 atmospheres of pressure.
The Sci-Med cutting balloon (Boston Scientific) was em-
ployed in those cases where the stenosis was particularly
unable to be resolved with either of the conventional
balloons.
Intravascular stent deployment took place with niti-
nol self-expanding S.M.AR.T.TM stents (Cordis Inter-
national). The stent was delivered under angiographic
guidance over the guide wire that had traversed the ve-
nous anastomosis. Stent sizes approximated the angio-
plasty balloon sizes used in the particular case, and ranged
from 8 mm to 12 mm in diameter and 20 mm to 80 mm in
length. The median length was 40 mm. The stent’s diam-
eter size utilized exceeded the maximal vessel diameter
by 1 to 2 mm in each case. The length of the stent used
was determined by the length of the lesion to be covered,
allowing for approximately 10 mm of the edge of the stent
to cover normal-appearing vessel.
Mechanical thrombectomy was performed with the
HELIXTM Clot Buster thrombectomy device (Microvena
Corporation, White Bear Lake, MN, USA) with in-
tragraft administration of heparin. An additional Brite
TipTM sheath at the opposite limb of the graft was neces-
sary in all cases to complete mechanical thrombectomy
and evaluate for arterial lesions. Repeat angiography was
performed through the sheaths once the procedure was
completed.
Percutaneous treatment of the venous anastomosis was
avoided if the guide wire could not safely traverse the le-
sion, or if the thrombosis occurred in the immediate post-
operative period of graft creation or revision (less than
10 days). Intravascular stent deployment was not used in
lesions for which angioplasty alone remedied the prob-
lem, and no recent (less than 3 months) percutaneous
or surgical procedure was necessary on the graft. Stent
deployment was also avoided if there were resistant cen-
tral venous stenoses that could not be remedied by usual
percutaneous techniques, including central venous stent
placement.
Patients received clopidrogel 300 mg immediately after
stent placement, and 75 mg daily for at least 4 weeks
after the procedure. Only patients with stent placement
received clopidrogel.
Patients were followed for graft patency, survival, and
the need for repeat percutaneous procedures. If repeat
percutaneous procedures were performed for thrombosis
or poor flows, the location of lesions, including intrastent
and central venous lesions, was noted and treated appro-
priately with angioplasty and additional stent placement
if needed.
The study is not a randomized controlled trial, but an
observational study. In addition to the above for patients
who received stents, we collected data on patients dur-
ing the current study period that received thrombectomy
and percutaneous intervention without stent placement
at our institution. Due to the nature of the referral net-
work for vascular interventions at our institution, only
patients at the dialysis facility adjacent to the university
hospital were available for full follow-up after thrombec-
tomy without stent placement.
Descriptive statistics were performed for the patient
demographics. Frequencies (percentages) were utilized
for nominal level characteristics, and measures of cen-
tral tendency and variability were utilized for contin-
uous level characteristics. Comparison of the duration
of graft survival between secondary unassisted patency
with primary patency was assessed using Kaplan-Meier
analysis.
RESULTS
Two hundred eleven patients were evaluated for clot-
ted AV grafts. Thirty-four patients had intravascular stent
placement at the venous anastomosis. Among these, all
except one were available for follow-up analysis at one
month. This one patient expired from unrelated causes.
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Table 1. Patient demographics
Frequency (%)
Gender
Male 18 (53%)
Female 16 (47%)
Race
Caucasian 4 (12%)
African American 29 (85%)
Asian/Pacific Islander 1 (3%)
Age (placement of stent) years
Median (min-max) 59 (29–87)
Reason for renal failure
DM 6 (18%)
HTN 13 (39%)
Diabetes and hypertension 7 (21%)
Lupus 2 (5%)
Heroin abuse 1 (3%)
Nephrectomy 1 (3%)
Obstructive neuropathy 1 (3%)
Renal cell cancer 1 (3%)
Unknown 2 (5%)
Location of access
Upper arm 19 (56%)
Forearm 13 (38%)
Leg 2 (6%)
Reason stent placed
Residual stenosis 20 (58%)
Elastic recoil 7 (21%)
Multiple previous angioplasties 7 (21%)
Thirty-two were available for follow-up analysis at six
months, and 14 were available for follow up at 12 months.
Variable numbers available for follow-up are a reflection
of the variable times during the 18 months of study that
individuals had their individual percutaneous procedures
performed.
Demographic information available among the popu-
lation studied suggests that the average age at the time
of stent deployment was 59 years, and the average dura-
tion of time with end-stage renal disease was 4.8 years.
Eighty-five percent was African American. Forty-seven
percent was female. Forty-five percent was diabetic. The
average age of the grafts studied was 17.9 months (range
2 months to 72 months). Fifty-six percent of grafts were
in the upper arm, 38% in the lower arm, and 6% in the
leg. Eighty-four percent of patients had one or more en-
dovascular or surgical procedures for graft malfunction
prior to this episode of thrombectomy and stent place-
ment (Table 1).
Figure 1 demonstrates the life table analysis of grafts
after stent placement. Notably, continued graft survival
6 months after stent placement was 88%, and 86% at
12 months. This is overall graft survival, otherwise known
as assisted patency or secondary patency. Survival with-
out the need for an additional procedure (referred to as
unassisted patency or event-free survival or primary pa-
tency) was 63% at 6 months and 36% at 12 months.
Among those patients requiring repeat procedures for
graft survival after stent placement [21], the majority
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Fig. 1. Life table analysis of probability of graft patency.
(81%) had new lesions found outside of the stent at the
time of repeat angiography. In 38% of cases, lesions were
found both outside of the stent and within the stent. In
43% of cases of repeat procedures, the original lesion
at the venous anastomosis (intra-stent) was not impli-
cated as the cause of graft dysfunction because the stent
had remained patent. In these patients, new lesions were
found only outside of the stent. Among those patients
requiring additional interventions after stent placement
to maintain graft function, only one required multiple
procedures at 6 months of follow-up. The rate of repeat
procedures among surviving grafts was 0.72 per graft year
post-thrombectomy and stent placement.
Evaluation of the 16 grafts no longer in use at the end
of follow-up revealed that they fell into distinct groups.
Four grafts were removed because of infection unrelated
to any percutaneous endovascular procedures. Two pa-
tients died with functioning grafts. Two grafts were aban-
doned while functioning because multiple aneurysms in
the graft led the surgeon to make the judgment that aban-
donment was better than surgical intervention in treat-
ing the aneurysms. The grafts were, however, functioning
well at the venous anastomosis stent sites. In five patients,
severe stenoses within the graft hampered adequate dial-
ysis flow and new graft placement was necessary. In
three patients, spontaneous thrombosis and patient and
nephrologist desire for new graft placement dictated
abandonment.
All in all, 6 of 16 grafts (37%) were abandoned due
to unrelated infections or patient death and not due to
graft failure. Seven of 16 grafts (44%) were abandoned
secondary to disease that occurred in an area distinct from
the venous anastomosis. Finally, in only 3 of 16 grafts
(19%) could the venous anastomosis lesion be implicated
as the cause of graft abandonment.
Table 2 demonstrates the 6-month total survival and
event-free survival rates based upon the location of the
graft.
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Table 2. Survival data based upon graft location in 6-month
follow-up group
Overall Upper arm Lower arm Leg
(N = 32) (N = 18) (N = 13) (N = 1)
Survival 28 (88%) 15 (83%) 12 (92%) 1 (100%)
Event free 20 (63%) 12 (67%) 7 (54%) 1 (100%)
There were 35 patients from the dialysis unit adjacent
to the university hospital available for full follow-up af-
ter thrombectomy without stent placement during the
same time period. The three months’ unassisted patency
(event-free survival) was 40%, and the assisted patency
rate (overall survival) was 46% after thrombectomy. Six-
month event-free survival (unassisted patency) was 12%,
and 12-month event-free survival was 0%. Assisted pa-
tency was 29% at 6 months and 3% at 12 months. Mean
graft survival after thrombectomy was 4.2 months (range
0 days to 13 months) in these patients with thrombec-
tomies and no stents.
DISCUSSION
These data suggest that when intravascular stents
are placed at the venous anastomosis of clotted PTFE
grafts, patency and longevity may be improved, but this
improvement depends upon repeated percutaneous pro-
cedures. The underlying process of vascular intimal hy-
perplasia continues unabated in other areas of the graft or
native vein, and in some cases recurs in the stent as well.
To interpret these findings in light of the previously pub-
lished literature regarding intravascular stents and dial-
ysis AV grafts, care should be taken to note the type of
stents and the adjunctive means utilized—surgical, per-
cutaneous, and medical for re-establishing flow.
Multiple reports note that primary patency of PTFE
dialysis grafts is low. Average grafts maintain patency
from 1 to 3 years, and most patients can expect multiple
procedures to maintain the patency. Some have reported
that in the natural history of PTFE grafts, 1.22 interven-
tions per graft year are necessary for maintaining access
patency [8]. Initial studies regarding salvage of AV grafts
had focused on the varying successes of endovascular ap-
proaches compared with surgical approaches. Multiple
studies in the late 1980s and early 1990s compared the
efficacy of surgical and percutaneous approaches in deal-
ing with thrombosed PTFE grafts [9]. A meta-analysis by
Mehta et al [10] revealed that the life expectancy of radio-
logically revised grafts was not shorter than those treated
surgically. Later, Gray [11] reported that the available
literature indicated that “percutaneous treatments are at
least as effective as surgery.”
Intravascular stents have been tried previously. Table 3
provides a summary of some trials involving stents and
dialysis grafts. Of note, only two previous trials consis-
tently evaluated thrombosed AV grafts requiring salvage
procedures [16, 17]. In the other trials, stents were placed
in grafts that had not yet clotted or had not previously
undergone interventions. It is difficult to compare previ-
ous stent trials that include patients with nonthrombosed
accesses because it has been well described that graft pa-
tency after thrombosis is significantly worse than patency
after elective percutaneous intervention. Similarly, it can
be presumed that trials in which stents were placed with-
out scrutiny to try evaluating a high-risk population for
graft abandonment (previous thromboses, previous pro-
cedures, current thrombosis) also would be less likely to
show a benefit in graft survival with stent placement, and
may not be comparable with the current study.
Turmel-Rodrigues et al [16] retrospectively evaluated
52 stents (Wallstents and Craggstents) placed in their in-
stitution in stenoses associated with PTFE grafts and AV
fistulas: 26 of these stents were placed in patients with
PTFE grafts and a graft thrombosis at the time of stent
placement. The indications for use of a stent were very
similar to the present study and included elastic recoil,
restenosis within 6 months, or iatrogenic vessel rupture.
They achieved impressive secondary patency rates for the
PTFE grafts of 100% at 6 months and 88% at 1 year.
Interestingly, they calculated the mean interval between
radiologic interventions before and after the stent was
placed. This interval increased to 2.1 times its pre-stent
duration, suggesting that the stent may have delayed the
need for repeat endovascular intervention.
Patel et al [17] report the utility of Wallstents in set-
tings with acute angioplasty failure, rapid restenosis, and
vessel perforation has occurred during treatment of graft
thrombosis and venous anastomotic stenoses. Among
26 lesions studied, technical success was 100%, and pri-
mary and secondary patency rates were 27% and 72% at
6 months, respectively. The secondary patency rate was
50% at 12 months.
It is important to keep in mind that all self-expanding
metallic stents are not similar in efficacy. This will limit
the ability to compare the present results with those of
earlier studies in which different types of stents were
used. The shape of the stent, the exact component ma-
terials, and efficacy in adherence to the vessel wall are
different among the various stents (Wallstent, Cragg,
Gianturco, S.M.A.R.T.). This idea is reflected in animal
studies, which demonstrate some differences, although
clinical trials comparing various stents and their rates of
restenosis have not been published with regard to the ve-
nous anastomosis. Treotola et al [18] compared Gianturco
Z stents with Wallstents in a canine model. These authors
found the Gianturco Z stent to have longer primary pa-
tency but more likelihood of stent fracture and necrotiz-
ing inflammation.
Use of similar materials but adding covering to the
stent can also change the effects of the stent on the lo-
cal vessel wall. Dacron-covered nitinol stents (covered
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Table 3. Summary of previous stent trials (uncovered stents)
No. of % at Immediate 6-month
PTFE grafts venous Salvage grafts Graft Clopidgel technical patency
Study Stent type stented anasto-mosis selected thrombosis with stent success advantage
Beathard [12] (1995) Gianturco 28 100% No No No Yes No
Hood [13] (1994) Not specified 20 35% Yes Not specified No Yes Yes
Gallego [14] (2000) Not specified 19 89% No No No Yes No
Hoffer [15] (1997) Wallstent 17 70% Yes Yes (27%) No Yes No
Turmel-Rodrigues Wallstent 26 100% Yes Yes No Yes Yes
[16] (1997) Craggstent
Patel [17] (1998) Wallstent 26 100% Yes Yes No Yes Yes
Cragg stents) used to treat angioplasty-related vessel per-
forations have not been demonstrated in small series to
prevent intimal hyperplasia, and actually cause increased
inflammatory reaction at the venous anastomosis com-
pared with Wallstents. [19] Recently, however, Ross [20]
demonstrated the clinical utility of a nitinol stent cov-
ered with PTFE graft material at the venous anastomosis,
adapting a strategy that has been used to treat aortoiliac
occlusive disease. Donaldson et al [21] reported primary
patency rates of 54% at 6 months and secondary patency
of 72% in a group of 12 patients (14 stents) using the same
product.
There has been no prior use of heparin and clopidro-
gel in conjunction with endovascular stents. Clopidrogel
was utilized in the current study to conform to other in-
terventionalists in the institution who utilize the medica-
tions with arterial stents in the coronary and peripheral
vascular systems. It is unclear whether this provided an
advantage in preventing in-stent restenosis and maintain-
ing graft patency.
At this point, the previously published literature does
not support the routine use of stents in venous anas-
tomotic lesions in nonthrombosed grafts referred for
angiogram by various intradialytic monitoring schemes
(Table 3). In the present study, stents were restricted
to patients who had immediate angioplasty failure or
repeated angioplasties with recurrent thrombosis, and
likely to have their grafts abandoned. Eighty-four per-
cent of patients had a previous percutaneous or surgical
procedure on the graft prior to thrombectomy and stent
placement, and most of these occurred in the two months
prior to stent placement.
While primary and secondary patency rates are impor-
tant, especially in comparison to natural history of grafts
that would have been abandoned or undergone surgical
correction, it cannot be overemphasized that immediate
patency achieved by stents, even if for a few weeks or
months, can help avoid temporary or long-term tunneled
dialysis catheter insertion while the patient waits for a
new surgically placed access to mature.
There is some concern that stent placement may jeop-
ardize future vascular access surgery. The need to place a
jump graft between the existing graft and a more proximal
vein, thereby bypassing the diseased venous anastomosis,
has specifically been touted by some as the reason to avoid
stent placement. Carefully sized stents that do not extend
much beyond the diseased anastomosis can prevent this
problem and preserve the native vein for surgery. In the
present study, stents covered the entire diseased segment
of vein and encroached into the healthy venous segment
by no more than 10 mm.
Also, this objection, raised mostly in the surgical lit-
erature, may not be applicable to the patients studied
in the present series. Placement of a jump graft to pre-
serve access function implies that both the PTFE graft
and the proximal vein are healthy and only the anasto-
mosis is severely diseased. The observations noted among
patients who required repeat interventions in the present
study suggest that the likelihood of this scenario is rather
limited. The majority of patients who needed repeat per-
cutaneous procedures had stenoses in areas outside of the
stent.
Another potential criticism of stent placement at the
venous anastomosis is that it prevents direct surgery of
the venous anastomosis. This type of surgery is known as
patch angioplasty. However, in many of the publications
regarding techniques of surgical correction of the venous
anastomosis and comparison of techniques of surgical
treatment of thrombosed grafts to endovascular treat-
ment, for unclear reasons patch angioplasty is limited to
a minority of salvage operations (12–18%) [22–24]. Also,
there is no data showing its superiority over any other
techniques, surgical or endovascular.
Finally, some have argued that stent placement may
preclude native AV fistula creation. Creation of fistulas,
usually in upper arm veins after forearm graft thrombo-
sis, is an innovative approach to increase the prevalence
of fistulas. However, this requires a healthy venous seg-
ment. In the present group of patients, great care was
taken to minimally encroach on the healthy venous seg-
ment, and not preclude the creation of a fistula at another
point in time. However, our data suggest that the venous
disease is progressive and not limited just to the venous
anastomosis. How this would affect the creation and pa-
tency of native vein fistula in this population remains to
be determined.
Sreenarasimhaiah et al: Salvage of thrombosed access grafts 683
With regard to evaluating the long-term results in the
stented patients in this study, care should be taken to
compare with the available literature regarding the two
distinct variables “graft patency” and “graft survival.” In
many articles, secondary patency rate refers to graft sur-
vival with additional procedures being performed after
the study treatment (surgery or endovascular procedure).
Primary patency refers to unassisted patency after the
study treatment has been utilized. This is certainly not
consistent, especially in previous literature.
What generally appears true is that overall graft sur-
vival is in the range of 1 to 3 years, and that multiple
procedures are necessary to maintain the full lifespan of
the graft. If the definitions are relied upon in the older
literature, the best case scenario for conventional ther-
apy of thrombosed grafts would give survival of 36%
at 6 months after thrombosis [2–4]. If the definition of
survival is flawed (based upon the portion of patients
who had surgical revisions, jump grafts, or secondary con-
version to fistulas), the best case scenario for assessing
the conventional therapy is to utilize the secondary pa-
tency rates for grafts of 59.8% at 2 years [5]. This fig-
ure comes from a large retrospective analysis of patients
in the United States Renal Data System Dialysis Mor-
bidity and Mortality Study. Even if the latter number is
used to compare conventional therapy (surgical or an-
gioplasty alone), the present study suggests that intravas-
cular stents offer a survival advantage for older grafts.
The average age of grafts in the study was 17.9 months,
and the data indicated 88% and 86% survival at 6 and
12 months after stent placement. These survival numbers
well exceed the expected 2-year survival numbers.
Again, we would emphasize that the current study was
not a randomized controlled study. However, our find-
ings in the 35 nonstented population of patients with
thrombectomies echo the dismal outcomes noted for
graft survival in the post-thrombectomy period with con-
ventional means of surgery and endovascular treatment
in the literature.
The Dialysis Outcome Quality Improvement (DOQI)
Guidelines recommend in guideline 21 that at 3 months
after a thrombectomy and angioplasty, unassisted pa-
tency rates (corresponding to event-free survival) should
exceed 50%. Similarly, the guidelines call for 50% unas-
sisted patency at 6 months and 40% unassisted patency
at 1 year if surgical thrombectomy with revision is per-
formed. This recommendation is listed as evidence-based
for the angioplasty guideline and opinion-based for the
surgical revision guideline. In those patients with stents,
these recommended values of patency are markedly sur-
passed at the 3, 6, and 12 month follow-up periods.
Figure 1 demonstrates this. Our patient population that
had thrombectomies but did not have stents at the ve-
nous anastomosis failed to meet these criteria; however,
this outcome is not dissimilar from the outcomes listed
in the current literature for post-thrombectomy graft
survival.
This study is interesting because it demonstrates that
patients who required repeated procedures often had
stenoses in areas outside of the intravascular stent, rather
than within the stent. This suggests that placement of the
stent did not affect the underlying disease process, caus-
ing graft or native vein disease. Equally important, it sug-
gests that treatment of the venous anastomosis lesion may
prolong graft life in significantly diseased grafts, provided
additional percutaneous procedures are utilized.
CONCLUSION
Indeed, intravascular stent placement may play a spe-
cific role in prolonging the lifespan of older dialysis grafts
that have already undergone previous percutaneous or
surgical procedures. This type of information is vital as the
dialysis population begins to outlive vascular access sites
and more importance is placed on graft salvage rather
than abandonment and fresh access creation.
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